127 related articles for article (PubMed ID: 7591208)
1. LOH and mutation analysis of CDKN2 in primary human ovarian cancers.
Campbell IG; Foulkes WD; Beynon G; Davis M; Englefield P
Int J Cancer; 1995 Oct; 63(2):222-5. PubMed ID: 7591208
[TBL] [Abstract][Full Text] [Related]
2. Deletion mapping of chromosome region 9p21-p22 surrounding the CDKN2 locus in melanoma.
Ohta M; Berd D; Shimizu M; Nagai H; Cotticelli M-G ; Mastrangelo M; Shields JA; Shields CL; Croce CM; Huebner K
Int J Cancer; 1996 Mar; 65(6):762-7. PubMed ID: 8631588
[TBL] [Abstract][Full Text] [Related]
3. Characterization of chromosome 9 in human ovarian neoplasia identifies frequent genetic imbalance on 9q and rare alterations involving 9p, including CDKN2.
Schultz DC; Vanderveer L; Buetow KH; Boente MP; Ozols RF; Hamilton TC; Godwin AK
Cancer Res; 1995 May; 55(10):2150-7. PubMed ID: 7743516
[TBL] [Abstract][Full Text] [Related]
4. Chromosome 9p allelic loss and p16/CDKN2 in breast cancer and evidence of p16 inactivation in immortal breast epithelial cells.
Brenner AJ; Aldaz CM
Cancer Res; 1995 Jul; 55(13):2892-5. PubMed ID: 7796417
[TBL] [Abstract][Full Text] [Related]
5. Alterations of CDKN2 (p16) in non-small cell lung cancer.
de Vos S; Miller CW; Takeuchi S; Gombart AF; Cho SK; Koeffler HP
Genes Chromosomes Cancer; 1995 Nov; 14(3):164-70. PubMed ID: 8589032
[TBL] [Abstract][Full Text] [Related]
6. Sporadic CDKN2 (MTS1/p16ink4) gene alterations in human ovarian tumours.
Schuyer M; van Staveren IL; Klijn JG; vd Burg ME; Stoter G; Henzen-Logmans SC; Foekens JA; Berns EM
Br J Cancer; 1996 Oct; 74(7):1069-73. PubMed ID: 8855976
[TBL] [Abstract][Full Text] [Related]
7. Infrequent CDKN2 mutation in human differentiated thyroid cancers.
Tung WS; Shevlin DW; Bartsch D; Norton JA; Wells SA; Goodfellow PJ
Mol Carcinog; 1996 Jan; 15(1):5-10. PubMed ID: 8561866
[TBL] [Abstract][Full Text] [Related]
8. p16 (CDKN2) is a major deletion target at 9p21 in bladder cancer.
Williamson MP; Elder PA; Shaw ME; Devlin J; Knowles MA
Hum Mol Genet; 1995 Sep; 4(9):1569-77. PubMed ID: 8541841
[TBL] [Abstract][Full Text] [Related]
9. The multiple tumor suppressor 1/cyclin-dependent kinase inhibitor 2 gene in human central nervous system primitive neuroectodermal tumor.
Raffel C; Ueki K; Harsh GR; Louis DN
Neurosurgery; 1995 May; 36(5):971-4; discussion 974-5. PubMed ID: 7791990
[TBL] [Abstract][Full Text] [Related]
10. Mutations of p16Ink4/CDKN2 and p15Ink4B/MTS2 genes in biliary tract cancers.
Yoshida S; Todoroki T; Ichikawa Y; Hanai S; Suzuki H; Hori M; Fukao K; Miwa M; Uchida K
Cancer Res; 1995 Jul; 55(13):2756-60. PubMed ID: 7796400
[TBL] [Abstract][Full Text] [Related]
11. Allelic loss of 9p21 and mutation of the CDKN2/p16 gene develop as early lesions during neoplastic progression in Barrett's esophagus.
Barrett MT; Sanchez CA; Galipeau PC; Neshat K; Emond M; Reid BJ
Oncogene; 1996 Nov; 13(9):1867-73. PubMed ID: 8934532
[TBL] [Abstract][Full Text] [Related]
12. High frequency of chromosome 9 deletion in ovarian cancer: evidence for three tumour-suppressor loci.
Devlin J; Elder PA; Gabra H; Steel CM; Knowles MA
Br J Cancer; 1996 Feb; 73(4):420-3. PubMed ID: 8595153
[TBL] [Abstract][Full Text] [Related]
13. Methylation of the 5' CpG island of the p16/CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing.
Gonzalez-Zulueta M; Bender CM; Yang AS; Nguyen T; Beart RW; Van Tornout JM; Jones PA
Cancer Res; 1995 Oct; 55(20):4531-5. PubMed ID: 7553622
[TBL] [Abstract][Full Text] [Related]
14. Low frequency of CDKN2 mutation in endometrial carcinomas.
Peiffer SL; Bartsch D; Whelan AJ; Mutch DG; Herzog TJ; Goodfellow PJ
Mol Carcinog; 1995 Aug; 13(4):210-2. PubMed ID: 7646759
[TBL] [Abstract][Full Text] [Related]
15. Mechanism of inactivation of CDKN2 and MTS2 in non-small cell lung cancer and association with advanced stage.
Nakagawa K; Conrad NK; Williams JP; Johnson BE; Kelley MJ
Oncogene; 1995 Nov; 11(9):1843-51. PubMed ID: 7478613
[TBL] [Abstract][Full Text] [Related]
16. Frequent mutations of CDKN2 in primary pancreatic adenocarcinomas.
Bartsch D; Shevlin DW; Tung WS; Kisker O; Wells SA; Goodfellow PJ
Genes Chromosomes Cancer; 1995 Nov; 14(3):189-95. PubMed ID: 8589035
[TBL] [Abstract][Full Text] [Related]
17. Loss of chromosome arm 9p DNA and analysis of the p16 and p15 cyclin-dependent kinase inhibitor genes in human parathyroid adenomas.
Tahara H; Smith AP; Gaz RD; Arnold A
J Clin Endocrinol Metab; 1996 Oct; 81(10):3663-7. PubMed ID: 8855819
[TBL] [Abstract][Full Text] [Related]
18. CDKN2 (MTS1) tumor suppressor gene mutations in human tumor cell lines.
Liu Q; Neuhausen S; McClure M; Frye C; Weaver-Feldhaus J; Gruis NA; Eddington K; Allalunis-Turner MJ; Skolnick MH; Fujimura FK
Oncogene; 1995 Mar; 10(6):1061-7. PubMed ID: 7700630
[TBL] [Abstract][Full Text] [Related]
19. Compilation of somatic mutations of the CDKN2 gene in human cancers: non-random distribution of base substitutions.
Pollock PM; Pearson JV; Hayward NK
Genes Chromosomes Cancer; 1996 Feb; 15(2):77-88. PubMed ID: 8834170
[TBL] [Abstract][Full Text] [Related]
20. Inactivation of p16/CDKN2 and p15/MTS2 genes in different histological types and clinical stages of primary ovarian tumors.
Ichikawa Y; Yoshida S; Koyama Y; Hirai M; Ishikawa T; Nishida M; Tsunoda H; Kubo T; Miwa M; Uchida K
Int J Cancer; 1996 Dec; 69(6):466-70. PubMed ID: 8980248
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
